Plus Therapeutics Inc (PSTV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Plus Therapeutics Inc (PSTV) has a cash flow conversion efficiency ratio of -0.522x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.24 Million) by net assets ($11.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Plus Therapeutics Inc (PSTV) balance sheet quality index to measure how much of total assets are equity-financed.
Plus Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Plus Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Plus Therapeutics Inc to evaluate the quality of earnings relative to operating cash generation.
Plus Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Plus Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Embrace Change Acquisition Corp Ordinary Shares
NASDAQ:EMCG
|
0.015x |
|
Kwang Myung El
KO:017040
|
0.147x |
|
Madison Pacific Properties Inc.
TO:MPC
|
0.019x |
|
Busan Ind
KO:011390
|
-0.035x |
|
VisDynamics Holdings Bhd
KLSE:0120
|
0.003x |
|
Sangsin Brake
KO:041650
|
-0.048x |
|
Athira Pharma Inc
NASDAQ:ATHA
|
-0.698x |
|
Korea Circuit Co Ltd
KO:007815
|
0.038x |
Annual Cash Flow Conversion Efficiency for Plus Therapeutics Inc (1998–2025)
The table below shows the annual cash flow conversion efficiency of Plus Therapeutics Inc from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see PSTV market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.00 Million | $-20.77 Million | -5.199x | -540.83% |
| 2024-12-31 | $-8.95 Million | $-10.55 Million | 1.179x | -87.63% |
| 2023-12-31 | $-1.35 Million | $-12.85 Million | 9.533x | +573.66% |
| 2022-12-31 | $6.45 Million | $-12.97 Million | -2.013x | -112.16% |
| 2021-12-31 | $10.84 Million | $-10.28 Million | -0.949x | +65.91% |
| 2020-12-31 | $3.03 Million | $-8.43 Million | -2.783x | +45.35% |
| 2019-12-31 | $1.16 Million | $-5.91 Million | -5.091x | -122.15% |
| 2018-12-31 | $5.22 Million | $-11.97 Million | -2.292x | -64.35% |
| 2017-12-31 | $13.00 Million | $-18.13 Million | -1.394x | +21.57% |
| 2016-12-31 | $10.99 Million | $-19.53 Million | -1.778x | -6.03% |
| 2015-12-31 | $12.21 Million | $-20.47 Million | -1.677x | -131.53% |
| 2014-12-31 | $-5.70 Million | $-30.33 Million | 5.319x | +148.20% |
| 2013-12-31 | $3.13 Million | $-34.56 Million | -11.035x | -121.27% |
| 2012-12-31 | $6.46 Million | $-32.19 Million | -4.987x | -40.43% |
| 2011-12-31 | $9.95 Million | $-35.32 Million | -3.551x | -244.59% |
| 2010-12-31 | $22.87 Million | $-23.57 Million | -1.031x | -115.84% |
| 2009-12-31 | $-3.66 Million | $-23.81 Million | 6.508x | +50.42% |
| 2008-12-31 | $-7.72 Million | $-33.39 Million | 4.327x | +35.59% |
| 2007-12-31 | $-9.40 Million | $-30.00 Million | 3.191x | +109.33% |
| 2006-12-31 | $-10.81 Million | $-16.48 Million | 1.524x | +762.42% |
| 2005-12-31 | $-6.23 Million | $-1.10 Million | 0.177x | +118.04% |
| 2004-12-31 | $12.83 Million | $-12.57 Million | -0.980x | -101.63% |
| 2003-12-31 | $14.91 Million | $-7.25 Million | -0.486x | -83.45% |
| 2002-12-31 | $26.00 Million | $-6.89 Million | -0.265x | -22.50% |
| 2001-12-31 | $38.49 Million | $-8.32 Million | -0.216x | -257.74% |
| 2000-12-31 | $49.34 Million | $-2.98 Million | -0.060x | -107.28% |
| 1999-12-31 | $-6.15 Million | $-5.11 Million | 0.831x | +105.89% |
| 1998-12-31 | $108.00K | $-1.52 Million | -14.102x | -- |
About Plus Therapeutics Inc
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric br… Read more